|
Volumn 37, Issue 2, 2005, Pages 920-922
|
Assessment of two strategies of Neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic, steroids, and anti-IL2R antibodies: 12-Month results of a randomized, multicentre, open, prospective controlled study
a b c
b
CHU RANGUEIL
(France)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BASILIXIMAB;
CREATININE;
CYCLOSPORIN A;
DACLIZUMAB;
IMMUNOSUPPRESSIVE AGENT;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
MYCOPHENOLIC ACID;
STEROID;
ADULT;
ANEMIA;
CANCER;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CREATININE CLEARANCE;
DEMOGRAPHY;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
HUMAN;
HUMAN TISSUE;
IMMUNOSUPPRESSIVE TREATMENT;
INCIDENCE;
KIDNEY DYSFUNCTION;
KIDNEY FUNCTION;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
LEUKEMIA;
LEUKOPENIA;
LUNG CANCER;
LYMPHOMA;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
RANDOMIZATION;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
TREATMENT FAILURE;
URINARY TRACT INFECTION;
|
EID: 17844401243
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/j.transproceed.2004.12.263 Document Type: Conference Paper |
Times cited : (5)
|
References (4)
|